Chronic clofibrate therapy in maintenance hemodialysis patients

21 hypertriglyceridemic hemodialysis patients were treated with 1--2 g/week of clofibrate. The dosage reduction from the usual clofibrate dose of 14 g/week avoided toxicity and corrected the abnormalities in serum triglyceride and high density lipoprotein cholesterol levels to or toward normal.